Corrigendum: Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors (Annals of Oncology (2012) 23 (463–471) (DOI: 10.1093/annonc/mdr137)

J. C. Soria; J. Cortes; C. Massard; J. P. Armand; D. De Andreis; S. Ropert; E. Lopez; A. Catteau; J. James; J. F. Marier; M. Beliveau; R. E. Martell; J. Baselga

doi:10.1093/annonc/mdy532

Corrigendum: Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors (Annals of Oncology (2012) 23 (463–471) (DOI: 10.1093/annonc/mdr137)

J. C. Soria, J. Cortes, C. Massard, J. P. Armand, D. De Andreis, S. Ropert, E. Lopez, A. Catteau, J. James, J. F. Marier, M. Beliveau, R. E. Martell, J. Baselga

Résultats de recherche: Contribution à un journal › !!Comment/debate

2 Citations (Scopus)

Résumé

In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga: JB is the consultant and on the advisory board for Roche and Novartis.

langue originale	Anglais
Numéro d'article	mdy532
Pages (de - à)	1020
Nombre de pages	1
journal	Annals of Oncology
Volume	30
Numéro de publication	6
Les DOIs	https://doi.org/10.1093/annonc/mdy532
état	Publié - 1 juin 2019

Accès au document

10.1093/annonc/mdy532

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Soria, J. C., Cortes, J., Massard, C., Armand, J. P., De Andreis, D., Ropert, S., Lopez, E., Catteau, A., James, J., Marier, J. F., Beliveau, M., Martell, R. E., & Baselga, J. (2019). Corrigendum: Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors (Annals of Oncology (2012) 23 (463–471) (DOI: 10.1093/annonc/mdr137). Annals of Oncology, 30(6), 1020. Article mdy532. https://doi.org/10.1093/annonc/mdy532

@article{f7857049c1964c718c0aca85326fab42,

title = "Corrigendum: Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors (Annals of Oncology (2012) 23 (463–471) (DOI: 10.1093/annonc/mdr137)",

abstract = "In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga: JB is the consultant and on the advisory board for Roche and Novartis.",

author = "Soria, {J. C.} and J. Cortes and C. Massard and Armand, {J. P.} and {De Andreis}, D. and S. Ropert and E. Lopez and A. Catteau and J. James and Marier, {J. F.} and M. Beliveau and Martell, {R. E.} and J. Baselga",

year = "2019",

month = jun,

day = "1",

doi = "10.1093/annonc/mdy532",

language = "English",

volume = "30",

pages = "1020",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "6",

}

Soria, JC, Cortes, J, Massard, C, Armand, JP, De Andreis, D, Ropert, S, Lopez, E, Catteau, A, James, J, Marier, JF, Beliveau, M, Martell, RE & Baselga, J 2019, 'Corrigendum: Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors (Annals of Oncology (2012) 23 (463–471) (DOI: 10.1093/annonc/mdr137)', Annals of Oncology, VOL. 30, Numéro 6, mdy532, p. 1020. https://doi.org/10.1093/annonc/mdy532

Corrigendum: Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors (Annals of Oncology (2012) 23 (463–471) (DOI: 10.1093/annonc/mdr137). / Soria, J. C.; Cortes, J.; Massard, C. et al.
Dans: Annals of Oncology, Vol 30, Numéro 6, mdy532, 01.06.2019, p. 1020.

Résultats de recherche: Contribution à un journal › !!Comment/debate

TY - JOUR

T1 - Corrigendum

T2 - Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors (Annals of Oncology (2012) 23 (463–471) (DOI: 10.1093/annonc/mdr137)

AU - Soria, J. C.

AU - Cortes, J.

AU - Massard, C.

AU - Armand, J. P.

AU - De Andreis, D.

AU - Ropert, S.

AU - Lopez, E.

AU - Catteau, A.

AU - James, J.

AU - Marier, J. F.

AU - Beliveau, M.

AU - Martell, R. E.

AU - Baselga, J.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga: JB is the consultant and on the advisory board for Roche and Novartis.

AB - In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga: JB is the consultant and on the advisory board for Roche and Novartis.

UR - http://www.scopus.com/inward/record.url?scp=85071029603&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy532

DO - 10.1093/annonc/mdy532

M3 - Comment/debate

C2 - 30624604

AN - SCOPUS:85071029603

SN - 0923-7534

VL - 30

SP - 1020

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

M1 - mdy532

ER -

Soria JC, Cortes J, Massard C, Armand JP, De Andreis D, Ropert S et al. Corrigendum: Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors (Annals of Oncology (2012) 23 (463–471) (DOI: 10.1093/annonc/mdr137). Annals of Oncology. 2019 juin 1;30(6):1020. mdy532. doi: 10.1093/annonc/mdy532